FDA Notices, Guidances Should Reflect St. John's Wort Interaction - CHPA
This article was originally published in The Tan Sheet
Executive Summary
Center for Drug Evaluation & Research health advisories and guidances should be amended to communicate potential interactions of St. John's wort with certain types of Rx drugs, CHPA tells FDA.
You may also be interested in...
HIV/AIDS, Cancer Cure Supplement Claims Targeted In Six FTC Actions
Western Dietary Products will preliminarily halt Internet marketing claims that its black walnut, wormwood and clove tinctures treat and cure diseases such as cancer, diabetes and HIV/AIDS, the Federal Trade Commission says.
Supplement Labeling Safety One Of Six Guidance Topics Raised By GAO
FDA should determine what type of safety information is required on dietary supplement and functional food labeling and release a guidance on the issue, the General Accounting Office states in a July 11 report. The GAO document also identifies five other issues pertaining to dietary supplements and functional foods where FDA guidances are needed.
St. John's Wort, Rx Drug Use Warning Adopted By CHPA
Consumer Healthcare Products Association member companies soon will be incorporating a prescription drug use warning on their St. John's wort supplements.